Dana-Farber Cancer Institute -Chestnut Hill

Newton, Massachusetts 02467

6 studies enrolling now · 25 studies all time

What they study most

ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Adenocarcinoma of Lung, Advanced Adrenal Gland Pheochromocytoma, Advanced Breast Cancer, Advanced Colorectal Cancer (Part 1), Advanced Gastric Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Paraganglioma, Advanced Renal Cell Carcinoma, Advanced or Metastatic Renal Cell Carcinoma

Studies at this site

• A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. — Recruiting now
• A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma — Recruiting now
• Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer — Recruiting now
• A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors — Recruiting now
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors — Recruiting now
• Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer — Recruiting now
• A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) — Recruiting now
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) — Running, not enrolling
• Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer — Running, not enrolling
• Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study — Running, not enrolling
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
• A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 — Running, not enrolling
• A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors — Running, not enrolling
• Study of PF-07265807 in Participants With Metastatic Solid Tumors. — Stopped early
• Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease — Running, not enrolling
• Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer — Running, not enrolling
• PF-07104091 as a Single Agent and in Combination Therapy — Running, not enrolling
• An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer — Completed
• A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer — Completed
• Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy — Running, not enrolling
• TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Running, not enrolling
• Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) — Running, not enrolling
• A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement — Stopped early
• Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors — Running, not enrolling
• PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors — Stopped early